{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:12:32Z","timestamp":1759482752215},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1923,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/ki.2010.225","type":"journal-article","created":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T08:42:18Z","timestamp":1280306538000},"page":"539-545","source":"Crossref","is-referenced-by-count":11,"title":["Have we fallen off target with concerns surrounding dual RAAS blockade?"],"prefix":"10.1016","volume":"78","author":[{"given":"Michael R.","family":"Lattanzio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2010.225_bb0010","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.225_bb0015","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.225_bb0020","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal dysfunction complicating the treatment of hypertension","volume":"347","author":"Palmer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.225_bb0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","article-title":"Longitudinal studies on the rate of decline in renal function with age","volume":"33","author":"Lindeman","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"10.1038\/ki.2010.225_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.225_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.ki.5002354","article-title":"The randomized clinical trial: an unbeatable standard in clinical research?","volume":"72","author":"Stel","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.225_bb0040","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2008.10.036","article-title":"The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point","volume":"53","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2010.225_bb0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.225_rf0050","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.225_bb0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)","volume":"4","author":"Fried","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.225_bb0060","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.225_bb0065","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.225_bb0070","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.225_bb0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study","volume":"45","author":"Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"10.1038\/ki.2010.225_bb0080","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.225_bb0085","first-page":"550","article-title":"Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria","volume":"92","author":"Anavekar","year":"2004","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2010.225_bb0090","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1681\/ASN.2005101101","article-title":"Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease","volume":"17","author":"Norris","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.225_bb0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","article-title":"Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy","volume":"45","author":"Atkins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.225_bb0100","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.225_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.225_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.diabres.2005.06.010","article-title":"Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension","volume":"71","author":"Sengul","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1038\/ki.2010.225_bb0115","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.225_bb0120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","article-title":"Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis","volume":"24","author":"Jennings","year":"2007","journal-title":"Diabet Med"},{"key":"10.1038\/ki.2010.225_bb0125","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2010.225_bb0130","doi-asserted-by":"crossref","first-page":"F37","DOI":"10.1152\/ajprenal.00519.2009","article-title":"Major role for ACE-independent intrarenal II ANG formation in type II diabetes","volume":"298","author":"Park","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2010.225_bb0135","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.225_bb0140","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/01.CIR.99.8.990","article-title":"Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure","volume":"99","author":"Hamroff","year":"1999","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.225_bb0145","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.225_bb0150","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.225_bb0155","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.225_bb0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.225_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1038\/ki.2010.225_bb0170","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815545870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815545870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T16:01:21Z","timestamp":1559318481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815545870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0085253815545870"],"URL":"https:\/\/doi.org\/10.1038\/ki.2010.225","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}